Abstract Purpose: The Wilms' tumor antigen 1 (WT1) is overexpressed in several leukemias and solid tumors, but there is currently limited information regarding its role in prostate cancer. This study aimed to investigateWT1expression in prostate cancer, and to determine the number and function of WT1-specificTcells in the peripheral blood of patients. Experimental Design: Immunohistochemistry was used to assess WT1 expression in cancer tissues. Human leukocyte antigen A2 (HLA-A2) tetramers served to detect WT1-specificTcells, and peptide-specific stimulation was used to assessT-cell function in vitro. Results: Immunohistochemistry of tissue arrays comprising 36 cancer and 8 normal prostate samples revealed nuclear WT1 staining in 39% of cancer samples, but not in normal prostate tissues. Tetramer analysis revealed a low frequency of WT1-specificTcells in 20 of 38 HLA-A2p ositive patients. In vitro stimulation with WT1 peptide plus interleukin 2(IL2) and interleukin 7 (IL7) did not lead to an accumulation of WT1-specific T cells in any of the patient samples, although all patients were able to generate T-cell responses against Melan-A/MART1 control peptide. Stimulation with WT1 peptide in the presence of interleukin 15 (IL15), a cytokine that was shown to reverse tolerance of murine tumor-specificTcells, was able to restore the expansion and IFNg production of WT1-specificTcells in a subgroup of prostate cancer patients. Conclusion: The observation that IL15 can restore the function of WT1-specificTcells that were unresponsive to IL2 has implications for vaccination and immunotherapeutic strategies that aim to enhanceWT1-specificTcell immunity in patients.
Prostate cancer is the most common cancer in men in
Europe and North America, and the incidence worldwide is increasing steadily (1) . The three most common treatment modalities, surgery, radiotherapy, and androgen ablation, are all associated with significant side effects and reduced quality of life (2) . It is therefore desirable to develop new immunotherapy options with the potential to selectively eliminate prostate cancer cells.
CTL are important effectors of antitumor immune responses (3) . The vast majority of CTL-recognized targets described to date are tumor-associated antigens such as the Wilms' tumor antigen (WT1), which is currently being evaluated for the immunotherapy of a number of leukemias and solid tumors. WT1 is an oncogene which is overexpressed in several leukemias and solid tumors including breast, lung, ovarian, and colon cancer (4 -8) , and WT1 expression levels have been shown to correlate with a poor prognosis in leukemia and breast cancer (9, 10) . In addition, blocking the action of WT1 with antisense oligomers prevented tumor cells from proliferating in vitro, suggesting that WT1 may contribute towards maintenance of the malignant phenotype (11, 12) .
There is currently limited information regarding the expression and immunogenicity of WT1 in prostate cancer. In this study we assessed WT1 expression in prostate cancer tissues, evaluated whether there were measurable WT1-specific CTL in patients, and whether these CTL were functional in vitro. WT1 immunohistochemistry was done on tissue arrays comprising 36 prostate cancer samples and 8 normal prostate samples, and a human leukocyte antigen (HLA)-A2/pWT126 tetramer was used to quantify WT1-specific T cells. Whereas 39% of prostate cancer samples showed nuclear WT1 staining, none of the normal prostate tissues showed nuclear staining for WT1 (P = 0.036). Tetramer-binding T cells were detected ex vivo in the peripheral blood of 20 of 38 (53%) patients with prostate cancer. The tetramer-positive T cells did not respond to antigen stimulation in the presence of interleukin 2 (IL2) and interleukin 7 (IL7). However, in a proportion of patients that did not respond to IL2/IL7, antigen stimulation with interleukin 15 (IL15) resulted in the accumulation of tetramer-positive T cells. Furthermore, cells cultured in the presence of IL15 produced IFNg in an antigen-specific manner.
Materials and Methods
Peripheral blood samples. Approval was granted by the Local Research Ethics Committee for the collection of blood samples from patients with prostate cancer after obtaining written consent. Peripheral blood mononuclear cells (PBMC) were separated from whole blood using density gradient centrifugation (Lymphoprep-Apogent Discoveries), and flow cytometry staining was carried out to determine the HLA-A2 status of the patient. Samples that were HLA-A2 -positive were used for subsequent experiments.
Peptides, tetramers, and flow cytometry. The peptides used in this study bound HLA-A*0201 and were derived from the Wilms' tumor antigen (pWT126, amino acid sequence RMFPNAPYL), and the melanoma-associated antigen Melan-A/MART1 (ELAGIGILTV), and were synthesized by ProImmune as described previously (13) . All peptides were dissolved in PBS and stored at a concentration of 2 mmol at -20jC. Phycoerythrin (PE)-labeled tetramers consisting of the same peptides bound to HLA-A*0201 molecules were obtained from Beckman Coulter. Tetramers have a mutation in the á-3 domain of the MHC molecule that reduces tetramer-binding to CD8 molecules (14) . Unless stated otherwise, all flow cytometric agents were purchased from BD Biosciences. All data acquisition was done on an LSR II flow cytometer (BD Biosciences) and analyzed using FACSDiva Software (BD Biosciences). To determine HLA-A2 status, cells were stained with FITC-conjugated anti-HLA-A2 antibodies (BB7.2 clone; AbD Serotec). Tetramer staining was done using PE-labeled tetramers on up to 3 Â 10 6 cells. Tetramer was added (3.3 Ag/mL) for 20 min at room temperature. Cells were washed once in PBS/1% FCS before being stained with directly conjugated antibodies to CD3 (FITC) and CD8 (allophycocyanin). Samples were incubated for 25 min at 4jC and then washed twice with PBS/1% FCS. Before data acquisition, cells were resuspended in 500 AL PBS/1% FCS. Propidium iodide was added to discriminate dead from viable cells.
Cell culture. The HLA-A2 -positive T2 cell line is deficient in the genes which encode the transporter associated with antigen processing. This results in inefficient loading of HLA class I molecules with endogenous peptides, allowing the HLA-A2 class I molecules to be efficiently loaded with exogenous peptides (15) . The T2 cell line was maintained in normal growth medium (NGM): RPMI 1640 (Invitrogen) supplemented with 10% heat inactivated FCS (BioWest), 1% penicillin, 1% streptomycin, and 2 mmol/L glutamine.
T cell culture. PBMCs were resuspended in NGM at a density of 3 Â 10 6 cells per 2 mL medium in a 24-well plate. The cytokines IL2 and IL7 were added to the medium on day 0 at concentrations of 20 units/mL (1 Roche unit = 3 IU; Roche) and 2.5 ng/mL (Roche), respectively. Alternatively, IL15 was added to the medium on day 0 at a concentration of 50 units/mL (R&D Systems). Peptide-specific stimulation was done by adding either the pWT126 or the pMelan-A/MART1 peptide directly to the medium (final concentration 10 Amol/L). After a culture period of 8 d, tetramer staining was done prior to restimulating the T cells. Restimulation involved plating the cells at a density of 5 Â 10 5 per 2 mL of T-cell medium containing IL2 at a concentration of 20 units/mL, or IL15 at a concentration of 50 units/mL. Cultures were stimulated using irradiated (80 Gy) T2 cells loaded with 100 Amol/L of the relevant peptide. Irradiated (30 Gy) autologous PBMC or PBMC from healthy HLA-A2 -positive donors obtained from the National Blood Service (Colindale, UK) were used as feeder cells.
Immunohistochemistry. Prostate cancer tissue array PR 951 was obtained from US Biomax Inc. A monoclonal antibody (NCL-L-WT1-562; Novocastra; refs. 16, 17) raised against a prokaryotic recombinant protein containing amino acids 1-181 of the NH 2 -terminus of the human WT1 protein was used for immunohistochemistry, which was done using standard protocols. Briefly, immunohistochemistry was done on 5-Am sections of formalin-embedded tissue arrays using the avidin-biotin peroxidase complex method (Ultra Vision, Lab Visio, Inc.). The primary anti-WT1 antibody was used at a 1:100 dilution for 30 min at 25jC. Heat-induced epitope retrieval was done by microwaving the slides in an EDTA solution for 20 min at 750 mW. Immunohistochemical staining was assessed by two independent researchers and classified into negative versus positive immunohistochemical staining, where negative was defined by control staining of skeletal muscle tissue, and positive was defined according to staining of WT1-expressing ovarian carcinoma tissue. Images (original magnification Â400) were obtained using an Olympus Camedia C-2000Z camera on a Olympus microscope model BX50 with UPlanApo objectives.
IFN ELISPOT assay. These were done using an IFN ELISPOT kit (BD Biosciences) according to the manufacturer's instructions. For ex vivo analysis, peptide (5 Amol/L) was added directed to PBMC (2 Â 10 5 / well) in 200 AL NGM and incubated for 20 h at 37jC, in triplicate. For the analysis of in vitro expanded T cells, autologous PBMC were used to present peptides to the expanded T cells. The ELISPOT assays were done in triplicate, with each well containing 2 Â 10 5 autologous PBMC, 5 Amol/L peptide, and 2 Â 10 5 responder T cells. After incubation for 20 h at 37jC, the cells were discarded and the plates were washed and developed with a second antibody to human IFNg (biotinylated) and streptavidin-alkaline phosphatase according to the manufacturer's instructions. ELISPOT wells containing responder T cells and autologous PBMC and irrelevant peptides served as negative controls. Stimulation of 5 Â 10 4 responder T cells with 200 ng/mL of staphylococcal enterotoxin B was used as a positive control. ELISPOT plates were read using an AxioCam MRc plate reader and KS Elispot software (Zeiss). Results are expressed as the mean number of spotforming units (SFU) per10 6 cells from triplicate wells.
Results
WT1 is overexpressed in prostate cancer. WT1 expression was assessed by doing immunohistochemistry on tissue array PR 951, which contained duplicate cores of 36 cases of prostate
Translational Relevance
Vaccination of cancer patients often results in an increased frequency of tumor antigen-specificTcells. Similarly, the adoptive transfer of CD4-positive and CD8-positive Tcells is an effective strategy to increase the number of antigen-specific T cells in vivo. However, continued tumor growth can occur despite the presence of tumor antigenspecificTcells.
In recent years, several tolerance mechanisms that can induceT-cell unresponsiveness in vivo have been identified in tumor-bearing hosts. The development of strategies to prevent and reverseT-cell unresponsiveness is an important area of ongoing research.
At present, interleukin 2 (IL2) is often used to improve the functional activity of adoptively transferred tumor antigen-specificTcells. In this study we show that interleukin15 (IL15) can rescue the functional activity of Tcells that were unresponsive to antigen stimulation with IL2. This study provides a rationale for the use of IL15 in cancer vaccination and adoptiveT-cell therapy.
cancer and 8 normal prostate tissue samples. Clinical characteristics are listed in Table 1 .
Immunohistochemistry was done using an IgG1 murine monoclonal antibody directed against amino acid 1-181 of the NH 2 -terminal of the human WT1 protein. All of the eight normal prostate samples displayed cytoplasmic staining for WT1, with none showing nuclear staining (Fig. 1A) . Of the adenocarcinoma samples, 34 (95%) showed cytoplasmic staining, of which 14 (39%) showed additional nuclear staining. Two (5%) did not stain with the WT1 antibody (Fig. 1A ). Where nuclear staining was present, it was heterogenous and the proportion of nuclei that were WT1-positive ranged from 30% to 60%. The difference in nuclear WT1 staining between normal and adenocarcinoma samples was statistically significant to P = 0.036 using Fisher's Exact test (Fig. 1B) . Neither the degree of differentiation of the tumors seen histologically (Gleason grade), nor the degree to which the tumor had spread locally to lymph nodes or to distant metastases (Tumor, Nodes, Metastases staging) was significantly associated with nuclear WT1 staining. Reproducibility between the duplicates was high: there was discordance for only one duplicate sample, where one core showed cytoplasmic staining only, and one showed cytoplasmic as well as nuclear staining.
WT1-specific T cells can be detected ex vivo in the peripheral blood of patients with prostate cancer. Using HLA-A2/pWT126 tetramers, we characterized the T-cell immune response to WT1 in prostate cancer patients. The HLA-A2 allele is expressed by (18, 19) . Prior to analyzing patient samples, we validated the HLA-A2/pWT126 tetramer to determine its specificity and sensitivity. A panel of PBMC from healthy HLA-A2 -positive donors was used to assess the level of background staining of the tetramer reagent. The PBMC were stained with anti-CD3 and anti-CD8 antibodies, and propidium iodide was used to gate out dead cells. For each sample, the same number of cells was stained with anti-CD3 and anti-CD8 antibodies in the absence and in the presence of PE-labeled tetramer. The flow cytometric analysis of the sample without tetramer was used to set the quadrants such that none of the viable CD3-positive CD8-positive T cells recorded as PE-positive. These quadrants were then used for the analysis of the sample stained with tetramer to record the number of viable CD3-positive CD8-positive T cells that bound tetramer. The analysis of 16 normal PBMC samples revealed that no more than 0.04% of viable CD3-positive CD8-positive T cells showed tetramer binding (Fig. 2A) . The mean of the tetramerpositive cells was 0.02%, with SD of 0.015. Thus, the mean plus 2 SD gave a value of 0.05%, which was used as a cutoff for background staining with the WT1 tetramer: PBMC samples containing z0.05% tetramer-binding cells were considered as positive. Using this cutoff, all PBMC from healthy individuals were tetramer-negative.
A high avidity HLA-A2 restricted, WT1-specific T cell line that showed bright staining with WT1 tetramers was used in cell mixing experiments with PBMC to determine the sensitivity of tetramer staining (20) . Decreasing numbers of WT1-specific T cells were added to 1 Â 10 6 PBMC. Staining was done and quadrants were set according to the strict criteria described above. Background staining with the tetramer in the PBMC population without added WT1-specific cells was 0.01% of CD3-positive CD8-positive T cells. The mixing of WT1-specific T cells with the PBMC resulted in a distinct population of tetramer-positive T cells that was readily detectable when as few as 150 WT1-specific T cells were added (Fig. 2B, iii) . Even when only 80 WT1-specific T cells were added, this resulted in increased tetramer staining from 0.01% in the control PBMC to 0.03% (Fig. 2B, i and ii) . Thus, although the WT1 tetramer can identify a very low frequency of WT1-specific T cells, its detection limit was set at 0.05% of viable CD3-positive CD8-positive T cells due to background staining in normal PBMC.
Peripheral blood was obtained from 100 prostate cancer patients, of which 38 were HLA-A2 -positive. The clinical characteristics of these patients are listed in Table 2 . Tetramer staining experiments were done with all HLA-A2 -positive patient samples applying the conditions that were used in the validation experiments described above. Figure 2C shows representative fluorescence-activated cell sorter plots of the tetramer staining profiles of 10 patients. Six patient samples scored positive as 0.05% or more of the CD3-positive CD8-positive T cells bound the WT1 tetramer. In total, 20 of 38 HLA-A2 -positive prostate cancer patients (53%) contained detectable frequencies of tetramer-binding T cells. The frequency of WT1 tetramer -binding cells was relatively low (range, 0.05-0.6% of CD3-positive CD8-positive T cells), and a large proportion of the positive cells showed dull tetramer binding.
The ex vivo ELISPOT analysis of patient PBMC samples did not detect peptide-specific IFNg production upon stimulation with pWT126 peptides (data not shown). This raised the possibility that ELISPOT assays were less sensitive than tetramer analysis, or that the WT1-specific T cells were functionally impaired and unable to produce IFNg. We therefore set up short-term T-cell cultures in order to increase the frequency of WT1-specific T cells.
WT1-specific T cells do not expand following in vitro culture with IL2 and IL7. Peripheral blood T cells from 20 prostate cancer patients were stimulated weekly for two rounds with pWT126 or control peptide pMelanA/MART1, in the presence of IL2 and IL7. All cultures accumulated a distinct population of MelanA/MART1-specific T cells, showing that the patients were immunocompetent and capable of generating peptidespecific T cell responses (Fig. 3A) . However, although pWT126-specific T cells were detectable ex vivo, the percentage of tetramer-positive cells did not increase after two rounds of peptide-specific stimulation (Fig. 3B) . Similar results were obtained with all 20 HLA-A2 -positive patient samples, suggesting a selective inability of the WT1-specific cells to respond to peptide stimulation. This T-cell unresponsiveness correlated with the results of ELISPOT assays, showing that the in vitro cultured T cells were unable to produce IFNg in a WT1-specific fashion (not shown). Together, these data suggest that the WT1-specific T cells in prostate cancer patients were tolerant and unable to proliferate or produce IFNg in response to peptide specific stimulation.
The unresponsive phenotype of WT1-specific T cells can be reversed by in vitro culture with IL15. It has been shown that IL15 can enhance the in vivo antitumor activity of CD8 T cells and also reverse the tolerant phenotype of tumor antigenspecific CD8-positive T cells (21 -25) . We therefore investigated whether IL15 was able to rescue the expansion and IFNg production of WT1-specific T cells from the blood of prostate cancer patients.
We had sufficient PBMC from eight HLA-A2 -positive patients, which had shown positive tetramer staining, to set up parallel stimulation cultures with pWT126 in the presence of IL2/IL7 or IL15. The PBMC were also stimulated with pMelanA/ MART1 as a positive control. As in previous experiments, all patients generated a distinct population of MelanA/MART1 tetramer -binding T cells, whereas stimulation with pWT126 and IL2/IL7 did not result in the accumulation of WT1-specific Fig. 2 . Validation of WT1tetramers and staining of patient Tcells. PBMC were stained with HLA-A*0201/pWT126 tetramer, anti-CD3 and anti-CD8 antibodies, and propidium iodide (PI). Dot plots, gated CD8-positive live lymphocytes. The percentage of CD8-positive CD3-positiveT cells that bound the tetramer is indicated in each plot. All PBMC samples were first stained with anti-CD3, anti-CD8, and propidium iodide in the absence of tetramer to set the quadrants such that no events were recorded in the top right quadrant. Following tetramer staining, the top right quadrant was used to record tetramer-bindingTcells. A, assessment of background staining with the WT1tetramer in PBMC from healthy individuals. HLA-A2^positive PBMC from healthy donors (H1-H10) were stained ex vivo. In total 16 healthy donors were analyzed, and the mean percentage of tetramer binding cells was 0.02%, with SD of 0.015. The mean plus 2 SD (0.05%) was used as cutoff for ''background'' tetramer binding. B, mixing experiments using PBMC and a WT1-specificTcell line were used to determine the detection limit of WT1tetramer staining. i) staining profile of PBMC without mixed WT1-specificTcells defined the tetramer background binding as 0.01%. ii-viii) tetramer staining profile of 10 6 PBMC mixed with 80-30,000 WT1-specificTcells. C, WT1tetramer staining of PBMC of prostate cancer patients. Shown are representative tetramer staining profiles of 10 patients; the percentages in bold indicate positive tetramer staining above background. In total 38 HLA-A2 patients were analyzed, and 20 patients (53%) showed tetramer binding (range, 0.05-0.6%).
T cells. However, in three of eight patients, culture with pWT126 and IL15 resulted in an expansion of WT1 tetramerbinding T cells (Fig. 4A) . The accumulation of tetramer-binding T cells in cultures supplemented with IL15 correlated with the detection of pWT126-specific T cells that were able to produce IFNg in ELISPOT assays (Fig. 4B and C) . As expected, the cultures stimulated in the presence of IL2/IL7 did not contain T cells capable of pWT126-specific IFNg production in the ELISPOT analysis, although stimulation with the positive control staphylococcal enterotoxin B resulted in IFNg production ( Fig. 4B and C) . Together, these data show that in some patients IL15 restored the functional activity of WT1-specific T cells that were unresponsive to peptide stimulation in the presence of IL2 and IL7.
Discussion
The immunohistochemistry data presented here showed nuclear WT1 expression in 39% (14 of 36) of prostate cancer samples, but not in normal prostate tissue. Similar results were recently reported by Devilard et al., describing nuclear WT1 expression in 44 of 85 (52%) prostate cancer samples (26) . This group showed that nuclear WT1 expression was more frequent in more advanced T 3 cancers (which extend through the prostate capsule) compared with T 2 cancers (which are enclosed within the capsule). This is consistent with the findings from our study, which showed that 14 of 29 T 3 /T 4 cancers showed nuclear WT1 expression, whereas all seven T 2 cancers in our series were negative for nuclear WT1 expression.
The WT1 expression in normal prostate epithelial cells was detectable in the cytosol but not in the nucleus. A recent study has also shown WT1 expression in normal lung epithelial cells where exposure to tumor necrosis factor á resulted in the translocation of WT1 from the nucleus to the cytosol (27) . The pathway mediating this effect involved protein kinase A phosphorylating residues in the zinc finger domain of WT1 protein, which was shown to disrupt DNA binding and result in WT1 translocation from the nucleus to the cytosol (28, 29) . In prostate cancer, the regulation of subcellular WT1 location seems disturbed, resulting in nuclear accumulation of this transcription factor in tumor cells. At present, it is not clear whether the nuclear translocation is associated with increased WT1 protein levels and/or increased WT1 peptide presentation by HLA class I molecules. To address this, further investigation using mass spectrometry and sequence analysis of peptides eluted from fresh tumor material would be required (30) .
We found a low frequency of WT1 tetramer -binding T cells in 53% of prostate cancer patients, suggesting that tumor cells had stimulated autologous T cell responses. This is consistent with previously published literature reporting a low frequency of WT1-specific T cells in patients with WT1-expressing malignancies. These studies have shown the presence of IFNgproducing, WT1-specific T cells in the peripheral blood of leukemia patients (31, 32) . Recent work showed an increase in the frequency of WT1-specific T cells following allogeneic stem cell transplantation, which correlated with a decrease in WT1 transcripts in the peripheral blood of leukemia patients, suggesting that WT1-specific CTL contributed to a reduction in the number of WT1-expressing leukemia cells (33) . Further evidence for the antitumor effect of WT1-specific CTL has been obtained in vaccination studies in patients with leukemia and solid tumors. A clear correlation was found between vaccineinduced T-cell responses and a reduction of tumor burden (34, 35) . Conversely, the loss of WT1-specific T cells was shown to correlate with the reappearance of WT1-expressing leukemia cells (35) . Together, the published studies have shown that WT1-specific T cells are detectable in patients, and that they are associated with antitumor effects after vaccination and after allogeneic transplantation.
The naturally occurring T cells in prostate cancer patients were functionally impaired and unable to expand upon WT1 peptide stimulation in the presence of IL2 and IL7. A similar observation was made recently in patients with leukemia, when naturally occurring WT1-specific T cells failed to expand upon WT1 peptide stimulation in the presence of IL2 and IL7. In this case, the unresponsiveness was due to regulatory T cells, as the removal of the CD4-positive CD25-positive T cell population Fig. 3A and B) . B, ELISPOTanalysis of patient Tcells after one round of in vitro expansion with pWT126 in the presence of IL2/IL7 or IL15. For the ELISPOTanalysisTcells were stimulated overnight with autologous PBMC in the presence or absence of pWT126 peptides. As a positive control,Tcell stimulation was done with autologous PBMC and staphylococcal enterotoxin B. As a negative control, the wells were seeded with only responderTcells. C, the ELISPOTresults are illustrated in a column graph (SFU, spot forming units). Peptide-specific IFNg production was detectable in all three patients that showed accumulation of tetramer-bindingTcells after expansion with IL15 (patient 37 after one round of stimulation is shown).
restored the ability of WT1-specific T cells to expand (36) . In our study, IL15 was able to restore the functional activity of WT1-specific T cells in three of eight patients tested. It is possible that regulatory CD4-positive CD25-positive T cells were responsible for T-cell suppression in those patients that did not respond to IL15.
Considering the similarity of the cytokine receptors for IL2 and IL15, it is surprising that IL15 restored the functional activity of tolerant T cells that did not respond to IL2. Both cytokines can bind to the low affinity receptor consisting of the common g chain and the h chain (CD122). The high affinity receptors consist of the g and h chain associated with the IL2 receptor a chain (CD25) or the IL15 receptor a chain. The intracellular signaling pathways that lead to distinct biological responses upon IL2 and IL15 binding are currently not well understood. In classical T cell anergy, IL2 was very effective in reversing T-cell unresponsiveness (37) . However, recent experiments in transgenic mice revealed that tolerance of T cells specific for a tumor-associated model antigen was not reversed by IL2, but was readily reversed by IL15 (21). Here we describe for the first time a similar situation in humans where T cells specific for a tumor-associated antigen are unresponsive to IL2, but recover functional activity when stimulated in the presence of IL15. Currently, IL2 is routinely used to enhance the functional activity of adoptively transferred tumor-reactive T cells in vivo. The data described here raise the possibility that IL15 may promote T-cell function in patients that do not respond to IL2 treatment.
The induction of T-cell unresponsiveness has been described in melanoma patients and in murine tumor models (38 -40) . Although immunogenic tumors stimulated antigen-specific T cell responses, these T cells were rendered nonfunctional and unable to control tumor growth (40) . Similarly, the adoptive transfer of tumor antigen-specific T cells resulted in transient tumor regression, which was then followed by progressive tumor growth associated with the induction of unresponsiveness in the transferred T cells (41) . The development of adjuvant cytokine treatment to protect the functional activity of tumor-reactive T cells is likely to improve the efficacy of tumor immunotherapy. 
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